112 related articles for article (PubMed ID: 15831599)
1. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.
Bagust A; Grayson AD; Palmer ND; Perry RA; Walley T
Heart; 2006 Jan; 92(1):68-74. PubMed ID: 15831599
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).
Amin AP; Reynolds MR; Lei Y; Magnuson EA; Vilain K; Durtschi AJ; Simonton CA; Stone GW; Cohen DJ
Am J Cardiol; 2012 Sep; 110(6):765-70. PubMed ID: 22651880
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.
Goeree R; Bowen JM; Blackhouse G; Lazzam C; Cohen E; Chiu M; Hopkins R; Tarride JE; Tu JV
Int J Technol Assess Health Care; 2009 Apr; 25(2):196-207. PubMed ID: 19331710
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of sirolimus-eluting stents.
Shrive FM; Manns BJ; Galbraith PD; Knudtson ML; Ghali WA;
CMAJ; 2005 Feb; 172(3):345-51. PubMed ID: 15684117
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation.
Varani E; Guastaroba P; Di Tanna GL; Saia F; Balducelli M; Campo G; Vignali L; Rossi R; Manari A; Piovaccari G; De Palma R; Marzocchi A
EuroIntervention; 2010 Apr; 5(8):953-61. PubMed ID: 20542781
[TBL] [Abstract][Full Text] [Related]
11. Hybrid coronary revascularization in the era of drug-eluting stents.
Murphy GJ; Bryan AJ; Angelini GD
Ann Thorac Surg; 2004 Nov; 78(5):1861-7. PubMed ID: 15511503
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit of drug eluting stents--time for a reality check.
Ward MR
Heart Lung Circ; 2005 Jun; 14(2):74-7. PubMed ID: 16352257
[TBL] [Abstract][Full Text] [Related]
14. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.
Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ
Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753
[TBL] [Abstract][Full Text] [Related]
15. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.
Yeh RW; Normand SL; Wolf RE; Jones PG; Ho KK; Cohen DJ; Cutlip DE; Mauri L; Kugelmass AD; Amin AP; Spertus JA
Circulation; 2011 Oct; 124(14):1557-64. PubMed ID: 21900079
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry.
Venkitachalam L; Lei Y; Stolker JM; Mahoney EM; Amin AP; Lindsey JB; Kennedy KF; Pencina MJ; Lopez JJ; Kleiman NS; Cohen DJ;
Circulation; 2011 Aug; 124(9):1028-37. PubMed ID: 21844081
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
[TBL] [Abstract][Full Text] [Related]
20. [Potential impact of drug-eluting stents in Sicily: results from a multicenter survey and cost-benefit analysis of drug-eluting stents versus bare metal stents].
Gulizia M; Martelli E; Tamburino C; Tolaro S; Frasheri A; Giambanco F; Grassi R; Fiscella A; Milazzo D
Ital Heart J Suppl; 2004 Aug; 5(8):630-8. PubMed ID: 15554018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
